Study: Immune-Boosting Antibody Treatment Isatuximab Meets Primary Endpoint for Multiple Myeloma
December 15th 2021This trial is the first to assess the use of isatuximab as a first-line treatment for newly diagnosed, transplant-eligible patients up to 70 years of age, according to the study authors.
Read More
PI3K Inhibitors May Help Prevent Tamoxifen-Associated Uterine Cancer in Patients With Breast Cancer
December 14th 2021Uterine cancers that developed in patients with breast cancer treated with tamoxifen had fewer phosphoinositol-3-kinase (PI3K) pathway mutations and may have been driven by tamoxifen-induced PI3K pathway activation.
Read More